$ROIV
SEC EDGAR Filings Hub
2 Filings
$ROIV · Roivant Sciences Ltd. SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for Roivant Sciences Ltd. ($ROIV) from November 9, 2026 through November 9, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
Check $ROIV portfolio concentration →
View $ROIV Congress trades →
Research $ROIV stock →
All SEC filings →
Total Filings2
10-K / 10-Q Reports1
8-K Material Events1
Form 4 Insider0
High-Impact1
Latest FilingNovember 9, 2026
Browse SEC Filings by Form Type
Latest $ROIV SEC Filings & AI Summaries (2)
November 9, 2026
$ROIV 10-Q — Roivant Sciences Ltd.
Roivant's first commercial product launch (LISRAYA) generated $31M in its first five weeks, validating the company's transition to a revenue-generating biotech.
November 9, 2026
$ROIV 8-K — Roivant Sciences Ltd.
Roivant's first commercial product launch and a positive registrational-trial readout mark a pivotal transition from clinical-stage to commercial biotech.
Related & Peer Company SEC Filing Hubs